RxDoctor Payments Data

Christopher Barnes, DO

Family Medicine · Grand Rapids, MINPI 1225079866

Payments from drug & device makers

$412in general payments, 2019–2025

Across 8 payments — averaging $51.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$280
  • Sanofi-aventis U.S. LLC$21
  • Novartis$21
  • Dexcom, Inc.$20
  • Smith+Nephew$18
  • Abbott$18
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$412100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$412 in reported general payments places this provider in the 55th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$44,458
Medicare patients
338
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$173,717
TrulicityDulaglutide125$160,324
OzempicSemaglutide75$113,439
JardianceEmpagliflozin74$86,180
MounjaroTirzepatide61$85,802
XareltoRivaroxaban22$28,427
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$27,255
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,905
Soliqua 100-33Insulin Glargine/Lixisenatide16$25,842
MyrbetriqMirabegron34$20,993
FarxigaDapagliflozin Propanediol17$12,482
Atorvastatin Calcium661$12,294
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$10,745
Levothyroxine Sodium433$9,511
DuleraMometasone/Formoterol23$8,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$18$246,126186 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$21$25,84216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →